- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02390284
Stop Retinal Ganglion Cell Dysfunction Study (STOP-RGCD)
Study Overview
Status
Conditions
Detailed Description
The PERG is recorded from small metallic buttons taped on the skin similarly to an electrocardiogram, with the difference that the electrodes are around the eyes.
The only physical contact you will experience is a gentle cleaning of the skin with an alcohol prep pad. During the test you must look with both eyes at a Television (TV) display for about 3 minutes. During the follow up period you may be asked to take one more PERG test lying down in a bed.
This will cause a momentary increase of your eye pressure similar to the one that occurs during your normal sleep. This may help to understand whether or not your optic nerve functions normally when the pressure in your eye increases. For OCT evaluation, the pupil has to be dilated with drops as you did before for your eye exam. You have to briefly look at a mark inside the instrument one eye at a time.
PERG and OCT will be performed during the same day of your visit with the eye doctor. If you have already done these tests in the past, as part of another study or as part of your standard treatment, the results of these tests will be obtained from your record, and be included in this study.
If you are a participant in the Observation Group, you will be monitored with PERG, OCT, and standard clinical examinations every six months until close of study. If you are a participant in the Medication Group you will be also treated with eye drop medicines.
RISKS:
There are certain risks and discomforts that may be associated with this research. You should be aware that you are at risk of developing glaucoma whether you participate in the study or not. It is not known whether the risk of developing glaucoma is reduced by eye drops to lower eye pressure; the study will attempt to answer this question.
For the PERG, the only significant risk to you is a small chance of a rash to the cleansing agent for skin electrodes, which should go away without treatment. For OCT, there is a rare risk to you of an allergic reaction to the drops used to dilate your pupils. The risk is even lower if you did not have any reaction during your previous eye exams. In case of an allergic reaction, your eye doctor will immediately treat it. If you had previous problems with pupil dilation, you may wish to speak to your eye doctor about the option of doing this additional test.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Bascom Palmer Eye Institute - University of Miami
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 to 85 years, inclusive
- Refractive errors within -5 to +3 diopters
- Best corrected visual acuity (BCVA) better than or equal to 20/30 (Snellen)
- Normal standard automated perimetry (SAP) according to the Ocular Hypertension Treatment Study (OHTS) criteria15 (reliability < 15% on all indices, normality > 5% on all global indices in two consecutive sessions 6 months apart)
- Minimum untreated Intraocular pressure IOP of 15 mm Hg
Glaucoma Suspect Status defined as one or more of the following:
- Glaucomatous optic disc appearance (vertical cup-to-disc ratio [C/D] ≥0.5
- Cup disc ratio asymmetry ≥0.2
- Localized thinning of the disc
- Presence or history of splinter disc hemorrhage
- Moderately increased IOP (>21 to <28 mm Hg).
- Family history of vision loss for glaucoma
Exclusion Criteria:
- Age-related macular degeneration
- Diabetes
- Parkinson's disease
- Multiple sclerosis
- Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits.
- Pregnant or nursing women.
- Currently using prescribed pressure lowering medicines and unwilling to be withdrawn from them.
- An OHTS risk score high enough in the judgment of the ophthalmologist or optometrist managing the patient to recommend pressure lowering medicine to the patient and not randomization.
- An OCT abnormal enough in a pattern consistent with glaucoma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Abnormal PERG Untreated
Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
|
|
Experimental: Abnormal PERG Treated
Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%. Drugs could be: Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation. If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure. |
Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
Other Names:
Lower intraocular pressure by increasing outflow of fluid from the eye.
Other Names:
Lower intraocular pressure by increasing outflow of fluid from the eye.
Other Names:
Lower intraocular pressure by decreasing production of fluid
Other Names:
Lowers intraocular pressure by decreasing intraocular fluid production
Other Names:
Lowers intraocular pressure by decreasing intraocular fluid production
Other Names:
Lowers intraocular pressure by decreasing intraocular fluid production
Other Names:
Lowers intraocular pressure by decreasing intraocular fluid production
Other Names:
|
No Intervention: Normal
Patients with a normal PERG test that will go through the study under observation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in retinal nerve fiber layer thickness
Time Frame: Baseline, 4 years
|
As measured by Optical Coherence Tomography
|
Baseline, 4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pattern Electroretinogram Amplitude
Time Frame: Baseline, 4 years
|
Assessed via Pattern Electroretinogram in microvolts
|
Baseline, 4 years
|
Change in Pattern Electroretinogram Phase
Time Frame: Baseline, 4 years
|
Assessed via Pattern Electroretinogram in degrees
|
Baseline, 4 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vittorio Porciattti, DSc, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Ocular Hypertension
- Glaucoma
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Enzyme Inhibitors
- Carbonic Anhydrase Inhibitors
- Natriuretic Agents
- Diuretics
- Anticonvulsants
- Pharmaceutical Solutions
- Ophthalmic Solutions
- Timolol
- Dorzolamide
- Acetazolamide
- Travoprost
- Brinzolamide
- Bimatoprost
- Latanoprost
- Methazolamide
Other Study ID Numbers
- 20140587
- R01EY014957 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Fondazione G.B. Bietti, IRCCSRecruiting
-
Nantes University HospitalNot yet recruiting
-
Intuor Technologies, Inc.Not yet recruitingOcular Hypertension | Glaucoma | Normal Tension GlaucomaUnited States
-
Amneal Pharmaceuticals, LLCCBCC Global Inc.; Amneal EU, LimitedNot yet recruitingOcular Hypertension | Open-angle GlaucomaUnited States
-
Qlaris Bio, Inc.Not yet recruitingGlaucoma | Open-angle Glaucoma (OAG) | Ocular Hypertension (OHT)
-
Elios Vision, Inc.Recruiting
-
Topcon CorporationNot yet recruiting
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruitingGlaucoma | Cytokines | Tear | Ultrasound Cyclo Plasty | Aqueous HumorChina
-
Johns Hopkins UniversityNational Eye Institute (NEI)Not yet recruiting
-
Universiti Sains MalaysiaHospital Universiti Sains MalaysiaNot yet recruiting
Clinical Trials on Latanoprost
-
EgymedicalpediaNot yet recruiting
-
Aneira Pharma, Inc.DataPharm Australia, CMAX Clinical Research, Agilex AustraliaNot yet recruiting
-
Aneira Pharma, Inc.RecruitingHypotrichosisUnited States
-
Uzoma Chinyei JoanRecruiting
-
Recep Tayyip Erdogan University Training and Research...Not yet recruitingGestational Diabetes
-
Otsuka Beijing Research InstituteRecruitingOpen Angle Glaucoma or Ocular HypertensionChina
-
PolyActiva Pty LtdRecruitingOcular Hypertension | Open Angle GlaucomaNew Zealand
-
Rigshospitalet, DenmarkLaboratoires TheaRecruitingOcular Hypertension | GlaucomaDenmark
-
Klinički Bolnički Centar ZagrebUniversity of ZagrebRecruitingOcular Hypertension | Primary Open-angle GlaucomaCroatia
-
Nicox Ophthalmics, Inc.RecruitingOcular Hypertension | Open Angle GlaucomaUnited States, China